BalixafortideCXCR4 antagonist · oncology research
Balixafortide was studied with eribulin in advanced breast cancer. The larger randomised trial did not confirm the hoped-for clinical advantage, an important distinction from earlier uncontrolled findings.
What is Balixafortide?
Balixafortide is an investigational CXCR4 antagonist studied alongside eribulin in advanced breast cancer. Early combination findings were followed by a larger comparative trial. 1 2
How it works
It blocks CXCR4 signalling, a pathway involved in cell trafficking and interactions with the surrounding tissue environment. That biological rationale does not establish an anticancer benefit.
Effects studied
Advanced breast-cancer treatment
FORTRESS did not demonstrate an efficacy advantage for adding balixafortide to eribulin on the reported progression, response or survival outcomes.
Evidence: Randomised trial reported in a primary conference abstract; early uncontrolled findings were not sufficient confirmation. 1 2
What does the evidence show?
Early combination study and checked FORTRESS abstract
A target in the tumour environment
Balixafortide blocks CXCR4, a receptor involved in cell movement and interactions with surrounding tissues. In cancer research, the idea was to disrupt signals that may help tumour cells persist or spread. That mechanism offered a hypothesis for combination treatment, not proof of benefit.
Why the early study was insufficient
An early study combined balixafortide with eribulin, a chemotherapy medicine. Without a randomised eribulin-only group, a response cannot establish how much the added drug contributed. The relevant next step was to compare the combination with the same chemotherapy given alone. 1
What the larger comparison reported
The FORTRESS conference abstract describes 432 enrolled patients and no improvement in response or progression-free survival with the combination. It also reports no observed overall-survival advantage in the analysed populations. This is a direct reason to avoid presenting balixafortide as an established breast-cancer treatment. 2
What the result means for further research
The result does not settle every possible use of CXCR4 inhibition, but it does limit this particular treatment claim. Infusion reactions were reported with the combination, so adding a biologically plausible agent also added treatment burden. Any further proposed use needs its own trial; the encouraging early study cannot establish that it will help. 2
Safety & status
Infusion reactions are a relevant tolerability concern. Combination-treatment adverse events also need to be distinguished from effects attributable to either agent alone. 1 2
Country and product status
Product indications and availability vary by country; current EU and Swiss status has not been independently checked for this draft.
Frequently asked questions
Why did early reports appear promising?
Uncontrolled combination studies cannot reliably separate drug effects from patient selection or the accompanying chemotherapy. 1
Did the larger trial confirm an advantage?
No efficacy advantage was demonstrated in the reported FORTRESS results. 2
Further reading
Sources
This entry was rewritten from our research archive. References below are reading leads unless a completed check is explicitly noted; a full independent evidence and regulatory review is still pending.
- Retained paper reference Archive research lead · Retained archive reference; not independently checked for this draft
- Kaufman et al. · FORTRESS phase 3 conference abstract Primary source checked · Primary conference abstract checked 27 October 2026: 432 enrolled; no observed efficacy advantage for balixafortide plus eribulin. Abstract-level assessment, not full trial audit.
Research provenance
This name was discovered in the Superpower peptide index, archived 26 October 2026. Its ratings and reviewer attribution have not been adopted as our own. The archive informed this original editorial draft; independent source review is still pending.